56 reports

Hoffman-La Roche (Roche) is one of the world' s largest biotechnology companies, covering a DIVERSE RANGE OF THERAPEUTIC AREAS INCLUDING ONCOLOGY, OPHTHALMOLOGY, NEUROSCIENCE, INFECTIOUS DISEASE, IMMUNOLOGY, CARDIOVASCULAR, AND METABOLIC DISEASE.

  • Type 2 Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

LIST OF COMPANIES AND ORGANIZATIONS ##.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Resverlogix Corp.
  • Vifor Pharma

Revati holds a PhD in Tumor Immunology from the Tata Cancer Research Institute in Mumbai, India.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 9.2.5 MALAYSIA

OUR COVERAGE EXTENDS TO THE MAJOR INDICATIONS ACROSS ALL THERAPY AREAS WITH A PARTICULAR FOCUS ON ONCOLOGY, CNS AND IMMUNOLOGY AND A WEIGHTING TOWARDS INDICATIONS DEMONSTRATING SIGNIFICANT INNOVATION IN EARLY-STAGE DEVELOPMENT.

  • Type 2 Diabetes
  • Market Size
  • AstraZeneca PLC
  • Novo Nordisk Group
  • Sanofi S.A.

THE COLLABORATION FOCUSES ON IMMUNOLOGY OF WOUND HEALING SPECIFICALLY THE ANTI-INFLAMMATORY PATHWAYS THAT APPEAR TO PLAY A SIGNIFICANT ROLE IN BOTH LIPID BARRIER SKIN DISEASES AS WELL AS CHRONIC WOUNDS.

  • Type 2 Diabetes
  • United States
  • MediWound Ltd.
  • TaiGen Biotechnology Co., Ltd.
  • ViroMed Co., Ltd.

MOLECULAR IMMUNOLOGY; ##(##-##): ##-##.

  • Type 2 Diabetes
  • United States
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.
  • KEY TAKEAWAYS
  • MERCK

As of 2015, one in ## adults had diabetes and this is expected to increase to one in ## by 2040.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • OMS-721 - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • ChemoCentryx, Inc.
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..3), H2 2018

It focuses on the development of antisense drugs in the areas of cancer treatment, respiratory diseases, immunology disorders and rare diseases.

  • Cell Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • ProMetic Life Sciences Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..3), H1 2019
  • DIABETIC NEPHROPATHY - PIPELINE BY ANTISENSE THERAPEUTICS LTD, H1 2019

It focuses on the development of antisense drugs in the areas of cancer treatment, respiratory diseases, immunology disorders and rare diseases.

  • Autoimmune Disease
  • Type 2 Diabetes
  • Australia
  • United States
  • Product Initiative
  • Dormant Projects, H2 2019

The activation of TGR## receptor stimulates glucagon-like peptide-## (GLP-##) secretion and controls the blood glucose level.

  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Ardelyx, Inc.

Published online 2014 Jan ##, Immunology The lysine deacetylase inhibitor Givinostat inhibits β-cell IL-##β induced IL-##β transcription and processing.

  • Insulin
  • Type 2 Diabetes
  • United States
  • MC2 Biotek Group
  • POXEL SA

Only one dose of RUCONEST was administered for ##% of the ## attacks. ## of ## patients experienced at least one treatment emergent adverse event within ## hours of completion of RUCONEST infusion.

  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Pharming Group NV
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..2), H2 2018

PATIENTS WERE RANDOMIZED ##:##:## TO EMPA ## MG.

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • DIABETIC FOOT ULCERS - PIPELINE BY FACTOR THERAPEUTICS LTD, H2 2018
  • DIABETIC FOOT ULCERS - PIPELINE BY FIRSTSTRING RESEARCH INC, H2 2018

It has pipeline candidates in oncology, immunology, neuroscience, metabolism, infectious disease and ophthalmology.

  • Chronic Disease
  • Therapy
  • Type 2 Diabetes
  • Wound Care
  • ViroMed Co., Ltd.
  • SMALL MOLECULES TO AGONIZE GLP1 AND GIP RECEPTORS FOR NON ALCOHOLIC STEATOHEPATITIS, OBESITY AND TYPE 2 DIABETES - DRUG PROFILE

Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects.

  • Digestive System Disorder
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • PIPELINE BY GLAXOSMITHKLINE PLC, H1 2018

It acts by targeting free fatty acid receptor ## (GPR##).

  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • GlaxoSmithKline plc

These results can be found online and will be published in Shock issue ##:##.

  • Type 2 Diabetes
  • United States
  • Company Operations
  • Product Initiative
  • Pharming Group NV
  • Oct 31, 2017: Visterra to Present New Preclinical Results on VIS649, Its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference

The company' s offers drugs for the treatment in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Autoimmune Disease
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • DIABETIC FOOT ULCERS - PIPELINE BY GENENTECH INC, H1 2018
  • DIABETIC FOOT ULCERS - PIPELINE BY FIRSTSTRING RESEARCH INC, H1 2018

Genentech develops drugs in several therapeutic areas including oncology, immunology, neuroscience, metabolism, infectious disease, ophthalmology and bioinformatics.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Wound Care
  • ProMetic Life Sciences Inc.

The company reported that subjects were randomized ##:##:## into one of three ophthalmic solution treatment groups: SkQ## ##. ## microgram/ mL, SkQ## ##. ## microgram/ mL, or ##. ## microgram/ mL (placebo).

  • Neurology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Santhera Pharmaceuticals Holding AG
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..2), H1 2018

The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others.

  • Cell Therapy
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • PIPELINE BY KOWA CO LTD, H1 2018
  • PIPELINE BY MERCK & CO INC, H1 2018

It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and women" s diseases, diabetes and vaccines.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative

Drake has served as one of the company s directors since September 2013.

  • Clinical Trial
  • Drug Development
  • Type 2 Diabetes
  • United States
  • AngioDynamics, Inc.
  • Indication Name
  • Pipeline by Johnson & Johnson, H1 2018

It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and women diseases, diabetes and vaccines.

  • Molecular Diagnostics
  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Product Initiative

THE MOLECULES DEVELOPED BY COMPANIES IN PHASE III, PHASE II, PRECLINICAL AND DISCOVERY STAGES ARE ##, ##, ## AND ## RESPECTIVELY.

  • Therapy
  • Type 2 Diabetes
  • Australia
  • World
  • Product Initiative

The drug candidates also down-regulate TNF-alpha and monocyte chemoattractant protein-##(MCP-##) mRNA expression and reducing the infiltration of neutrophils and pro-inflammatory monocytes.

  • Autoimmune Disease
  • Pathology
  • Therapy
  • Type 2 Diabetes
  • BioTherapeutics Inc.

Hatfield held a number of executive positions at Bristol-Myers Squibb (BMS), including Senior Vice President of BMS' s Immunology and Virology DivisionsPresident, BMS-Canada, and Vice President, U. S.

  • Healthcare
  • Type 2 Diabetes
  • United States
  • Company
  • Zafgen, Inc.
  • PROLIFERATIVE DIABETIC RETINOPATHY (PDR) - PIPELINE BY AERIE PHARMACEUTICALS INC, H2 2018
  • PROLIFERATIVE DIABETIC RETINOPATHY (PDR) - PIPELINE BY ACUCELA INC, H2 2018

Subjects will be randomly assigned to one of three treatment arms in a ##:##:## ratio.

  • Eye Disease
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Indication Name
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..7), H2 2017

The company develops drugs in therapeutic areas of ophthalmology, immunology, cardiovascular disease, dermatology and biobetter.

  • Obesity
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Omeros Corporation